TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Diagnosis and Treatment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of fluid loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Level of placental angiogenic factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical functioning
Endpoint domain: Life impact
Primary endpoint: Freedom from MALE-POD
Endpoint domain: Mortality/survival
Primary endpoint: Transverse-view vessel area loss percentage (TVAL%) of the target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Functional dyspepsia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients responders to pneumococcal polysaccharides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Defibrillation Thresholds (DFTs) (3.5 ms Waveform)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DFT (2.5 ms Waveform)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DFT (4.5 ms Waveform)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recidivism - Self report of arrests and undetected crimes
Endpoint domain: Adverse events/effects
Primary endpoint: Recidivism - Official FBI records of arrests
Endpoint domain: Adverse events/effects
Primary endpoint: absence of exposed bone, fistulae or ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from MAEs (at 30 Days)
Endpoint domain: Adverse events/effects
Primary endpoint: Preliminary Effectiveness (treatment and technical success)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Brentuximab Vedotin plus TAK228
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma eicosapentaenoic concentration (EPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of cCMV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number and type of maternal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number and type of fetal/neonatal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameters of pravastatin sodium during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intradialytic BP change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post traumatic Cognitions Inventory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: phenotype of meningococcal serogroup A specific B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urination regularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of anti-HAV positive tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum total serum bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of therapy based on drug screening results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of hyperreflective granulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to no longer show improvement from baseline RNKLS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of new nasal pillows mask
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occupational Balance Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Parkinson's Disease Quality of Life-8 (PDQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self Efficacy for Performing Energy Conservation Strategies Assessment (SEPECSA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Psoriatic Skin Infiltrate Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of serum IGF-1R-Abs above the upper normal levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Clinical Global Impression Scale - Improvement and Severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of participants free of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Favorable Response to Echinocandin Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Successful Treatment of Any Baseline Invasive Fungal Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mortality at Hospital Discharge
Endpoint domain: Mortality/survival
Primary endpoint: Change in plasma concentrations of amino acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in protein expression activity in tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptom change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient experience of transition of care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Parent Caregiver Interaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: ESCS Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the mean number of maximum asthma symptom days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of peripheral coronary artery bypass anastomotic structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: COPD Hospital Readmission/Death Within 6 Month of Discharge
Endpoint domain: Mortality/survival
Primary endpoint: Cesarean delivery rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rehospitalizations due to acute heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean maximal change of standing systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetic profile of INX-08189
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic profile of verapamil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of INX-08189
Endpoint domain: Adverse events/effects
Primary endpoint: Types of problems and toxicities encountered
Endpoint domain: Adverse events/effects
Primary endpoint: Change in plasma nitrate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in blister fluid leucocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Bleeding Episode With Treatment Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of daily anal gas evacuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of hypoperfused skin island
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin oxygen saturation of distal flap
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quality of life measured by KDQoL-SF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Antibody positive conversion rate of experimental groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titer (GMT) of 4 doses groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety within 30 minutes
Endpoint domain: Adverse events/effects
Primary endpoint: Western Ontario Rotator Cuff (WORC) Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Health-Promoting Lifestyle Profile II (HPLP II) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Short Form 36 Health Survey (SF-36) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of Center for Epidemiologic Studies Depression Scale (CES-D) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Venous thromboembolism events
Endpoint domain: Mortality/survival
Primary endpoint: Change in Clinical outcomes in routine evaluation outcome measure (CORE-OM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Eating Attitudes Test (EAT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-rated sleep quality score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Safety aspects
Endpoint domain: Adverse events/effects
Primary endpoint: NeuroCom Sensory Organization Test (SOT) composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in placental blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean usefulness score of SAGES Safe Cholecystectomy Rule
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of activated gamma delta T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With at Least One Symptomatic Hypoglycemic Event
Endpoint domain: Adverse events/effects
Primary endpoint: Heart Failure-specific Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Performance of WE-CT in detecting colon tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent change from baseline in Low Density Lipoprotein Cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants with an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Montgomery & Asberg Depression Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Psychiatric Rating Scale for Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression-Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood levels of GSK598809 and nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lipid profile modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in HbA1c level (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serum fasting insulin levels (pmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of regression to normoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial intact proinsulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Retinal vessels diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Capillary and Venous Results Within +/- 15mg/dL or +/- 20% of Laboratory Glucose Method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Psycho-emotional status pre-operative
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psycho-emotional status post-operative
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Annual Rate of Occurrence of Serious Bacterial Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Pedometer levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of adverse events assessed by CTC
Endpoint domain: Adverse events/effects
Primary endpoint: EPA as a percent of total fatty acids in red blood cell membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total and LDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Distance between the catheter tip and the carina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With Target Lesion Primary Patency (TLPP) at 6 Months Post Index Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants With Freedom From Any Serious Adverse Event(s) Involving the AV Access Circuit at 30 Days Post Index Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Dispersed Phaco energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of inflammatory cytokines concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interrater Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Atrial Fibrillation Induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in intensity of cortical arousals associated with periodic limb movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Freedom from device/system related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from pressure sensor failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized HF hospitalization rate at 1 year
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Pectoralis Minor Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline FVC (Forced Vital Capacity) (L) at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline FEV1 (Forced Expiratory Volume in 1 minute)(L) at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline Exercise Capacity assessed with 6-minute walk test at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Portion of patients with grade 3 or greater toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Oswestry Disability Index Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life assessed by Short Form-12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain Level assessed by McGill Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of babies requiring treatment for retinopathy of prematurity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in daily physical activity energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of immature myeloid cells in ovarian follicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients requiring invasive mechanical ventilation or dying
Endpoint domain: Mortality/survival
Primary endpoint: Blood troponin HS concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood copeptin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Final diagnosis of ACS non ST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutamate Metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Motor Impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in the Total Volume of HO Lesions as Assessed by Computed Tomography (CT) at Week 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time-Weighted Average (Standardized AUC) of the Percent Change From Baseline in Total Lesion Activity by 18^F-NaF PET at Week 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of PDA Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall time in target range (70-180 mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Voriconazole serum trough concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline on the Investigator's Global Assessment (IGA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualised height velocity (HV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HV SDS height velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with transportation services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptomatic response after palliative radiotherapy (bleeding)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptomatic response after palliative radiotherapy (pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal toxicity after the end of radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Genitourinary toxicity after the end of radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Pain score during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Allograft Vasculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ceftolozane-tazobactam activity against multidrug-resistant P. aeruginosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of carbapenemases in Enterobacteriaceae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Steady-state serum pharmacokinetics of raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progressive renal function loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to HbA1c >8%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 2 year-loco-regional control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention Without Relapse to Heroin Addiction
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Incidence of technical successful TPLA treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of TPLA treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Correct diagnosis of diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Alteration of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Alteration of metabolome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Summary of Clinical Safety Success
Endpoint domain: Adverse events/effects
Primary endpoint: progress of diabetic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: new onset and types of tumor in T2DM patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tolerability to pharmacological treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Change From Baseline in Post-dose Trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lipid parameter change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of patients achieving ATP III LDL goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probability of Survival at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Intubation with less hemodynamic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smooth Maintenance of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less postoperative pain killers
Endpoint domain: Adverse events/effects
Primary endpoint: Flu shot vaccination receipt
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention